Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
- Cadrenal Therapeutics expands evaluation of tecarfarin for antiphospholipid syndrome, a rare medical condition affecting 167,000 patients in the US.
- Tecarfarin aims to provide improved outcomes compared to warfarin.
- Market opportunity for tecarfarin in rare medical conditions exceeds $2 billion per year.
- None.
APS, formerly known as Hughes Syndrome or Sticky Blood in the
"Antiphospholipid syndrome is a rare medical condition and blood clotting disorder affecting approximately 167,000 patients in
Based on clinical data, market research, and insights from key industry experts, the Company believes tecarfarin is ideally positioned to target rare medical conditions where warfarin fails to achieve sufficiently stable anticoagulation and Direct Oral Anticoagulants (DOACs) are not widely prescribed. Currently, Cadrenal has identified three such rare medical conditions: End-Stage Kidney Disease (ESKD) with Atrial Fibrillation (AFib); Left Ventricular Assist Devices (LVADs); and Antiphospholipid Syndrome (APS). Based on management's market analysis studies and expected adoption rates, these three rare medical conditions present a U.S. market opportunity in excess of
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions. Tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, and atrial fibrillation. Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K antagonist (warfarin) used in the prevention of thrombosis. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements."
The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding patients with APS who receive direct oral anticoagulants (DOACs) having an increased risk for arterial thrombosis compared with those who receive Vitamin K antagonists (VKAs); effective anticoagulation (blood thinners) preventing health problems; tecarfarin being ideally positioned to target rare medical conditions where warfarin fails to achieve sufficiently stable anticoagulation and Direct Oral Anticoagulants (DOACs) are not widely prescribed; tecarfarin providing improved outcomes for patients with APS; and End Stage Kidney Disease (ESKD) with Atrial Fibrillation (AFib); Left Ventricular Assist Devices (LVADs); and Antiphospholipid Syndrome (APS) presenting at U.S. market opportunity in excess of
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to successfully advance tecarfarin for the treatment of rare medical conditions including patients with APS who require chronic anticoagulation; the ability to assess the size of the U.S. market opportunity for patients with End Stage Kidney Disease (ESKD) with Atrial Fibrillation (AFib); Left Ventricular Assist Devices (LVADs); and Antiphospholipid Syndrome (APS) and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-expands-evaluation-of-tecarfarin-for-patients-with-antiphospholipid-syndrome-aps-301913344.html
SOURCE Cadrenal Therapeutics, Inc.